Pharvaris (NASDAQ:PHVS) Price Target Lowered to $25.00 at Cantor Fitzgerald

Pharvaris (NASDAQ:PHVS) had its price objective decreased by Cantor Fitzgerald from $28.00 to $25.00 in a research note published on Wednesday morning,Benzinga reports. Cantor Fitzgerald currently has an overweight rating on the stock.

Separately, JMP Securities lifted their target price on shares of Pharvaris from $46.00 to $55.00 and gave the stock a “market outperform” rating in a research note on Friday, January 31st.

Pharvaris Stock Performance

Shares of NASDAQ:PHVS opened at $16.07 on Wednesday. The business’s fifty day moving average price is $15.35 and its two-hundred day moving average price is $17.78. The stock has a market cap of $840.30 million, a PE ratio of -5.74 and a beta of -2.85. Pharvaris has a one year low of $11.51 and a one year high of $25.50.

Pharvaris (NASDAQ:PHVS) last posted its quarterly earnings data on Tuesday, May 13th. The company reported ($0.89) EPS for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.09). As a group, equities research analysts predict that Pharvaris will post -2.71 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of PHVS. FMR LLC boosted its holdings in shares of Pharvaris by 3.6% in the 4th quarter. FMR LLC now owns 5,395,370 shares of the company’s stock valued at $103,429,000 after purchasing an additional 189,714 shares during the last quarter. Soleus Capital Management L.P. raised its position in shares of Pharvaris by 36.2% in the 4th quarter. Soleus Capital Management L.P. now owns 814,652 shares of the company’s stock worth $15,617,000 after buying an additional 216,483 shares during the period. Octagon Capital Advisors LP boosted its holdings in Pharvaris by 25.4% in the fourth quarter. Octagon Capital Advisors LP now owns 778,000 shares of the company’s stock valued at $14,914,000 after acquiring an additional 157,530 shares during the last quarter. Rock Springs Capital Management LP grew its position in Pharvaris by 2.4% during the fourth quarter. Rock Springs Capital Management LP now owns 775,131 shares of the company’s stock valued at $14,859,000 after acquiring an additional 18,200 shares during the period. Finally, Price T Rowe Associates Inc. MD increased its stake in Pharvaris by 36.4% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 443,896 shares of the company’s stock worth $8,510,000 after acquiring an additional 118,408 shares during the last quarter.

About Pharvaris

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.